BPA Call 75F40122A00008-75F40122F19009
Award Date 8/17/22
Potential Completion Date 8/17/23
Potential Value $412K
Federal Agency
Awardee
Ultimate Awardee
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price award from the Food and Drug Administration (FDA) to Booz Allen Hamilton Inc. for the Center for Drug Evaluation and Research (CDER) Office of Therapeutic Biologics and Biosimilars (OTBB) Biosimilar User Fee Act I Program. The $1,099,979.78 contract is for biosimilar and interchangeable product education, uptake, and implementation services. The award does not have a set-aside designation. Booz Allen Hamilton Inc. is a leading provider of management, technology, and...
- Booz Allen Hamilton Inc. was awarded a firm fixed price contract valued at $999,836.08 by the Department of Health and Human Services' Food and Drug Administration to provide services under the Center for Drug Evaluation and Research's Biosimilar User Fee Act Program. Specifically, Booz Allen Hamilton will support biosimilar and interchangeable product education, uptake, and implementation efforts. The contract was awarded through the Mission Oriented Business Integrated Services...
- This federal contract award from the Food and Drug Administration (FDA) is for the CDER Informatics Enterprise Service and Operation Modernization project. It is a $17,461,833.28 Blanket Purchase Agreement (BPA) call awarded to Booz Allen Hamilton Inc. under the Multiple Award Schedule (MAS) contract. The contract will provide informatics enterprise services and operations modernization support to the FDA's Center for Drug Evaluation and Research (CDER) over a 3-year period until January 2025....
- This federal contract was awarded by the Food and Drug Administration (FDA), a civilian agency, to Booz Allen Hamilton Inc., a leading management, technology, and engineering services firm. The contract, valued at $12,954,413.27, is a Blanket Purchase Agreement (BPA) call under the General Services Administration's (GSA) Information Technology (IT) Schedule 70 contract vehicle. The contract is for IT Lifecycle Development and Management Support services, with a period of performance through...
- This federal contract was awarded by the Food and Drug Administration (FDA) to Booz Allen Hamilton Inc. for $5,638,827.56 to develop a landscape assessment of evidentiary standards and establish evidentiary standards for the use of pharmacodynamic biomarkers in biosimilar drug development. The contract is a call under Booz Allen Hamilton's Mission Oriented Business Integrated Services (MOBIS) Blanket Purchase Agreement (BPA) with the FDA, which provides organizational change management and...
- This is a $9,183,143.60 Blanket Purchase Agreement (BPA) Call contract awarded by the Food and Drug Administration (FDA) to Booz Allen Hamilton Inc. for system development, modernization, and enhancement support services. The contract is not set-aside and utilizes the Multiple Award Schedule (MAS) contract vehicle. Booz Allen Hamilton is a leading provider of management, technology, and engineering services to the U.S. government, with expertise in defense, intelligence, and civil markets. The...
- This is a firm fixed price award to Booz Allen Hamilton Inc. for a pipeline assessment of pharmacodynamic biomarkers in biosimilar development on behalf of the Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services. The award, which has a potential value of $409,651.32, was made under the Mission Oriented Business Integrated Services (MOBIS) Federal Supply Schedule contract vehicle and does not have a set-aside designation. The period of performance for this...
- This is a federal contract award from the Food and Drug Administration (FDA) to Booz Allen Hamilton Inc., a prominent management, technology, and engineering services firm. The contract is for "Regulatory Science Optimization and Support" services, with a ceiling value of $3,802,146.30 and a performance period ending on September 21, 2028. The contract type is a Blanket Purchase Agreement (BPA) call, with a pricing structure of labor hours. The contract is not set aside for any...
- The U.S. Food and Drug Administration (FDA) awarded a Blanket Purchase Agreement (BPA) call worth up to $4,750,157.46 to Booz Allen Hamilton Inc. for a "Pharmaceutical Quality and Compliance Platform." This contract is under the Mission Oriented Business Integrated Services (MOBIS) Schedule, which is a General Services Administration (GSA) contract vehicle. The contract is for labor hours and does not have a set-aside designation. Booz Allen Hamilton Inc., a leading management,...
- The Food and Drug Administration awarded a Blanket Purchase Agreement (BPA) call with a ceiling value of $352,201.98 to Booz Allen Hamilton Inc. on July 11, 2024. This contract, which will be performed in West McLean, Virginia, supports the FDA's objective to procure technical and management consulting services for comprehensive planning and business operations improvements across the FDA enterprise. The contract utilizes a firm fixed-price pricing structure and carries no set-aside designation,...